Insmed Incorporated or Ionis Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

Biotech Giants: A Decade of SG&A Cost Management

__timestampInsmed IncorporatedIonis Pharmaceuticals, Inc.
Wednesday, January 1, 20143107300020140000
Thursday, January 1, 20154321600037173000
Friday, January 1, 20165067900048616000
Sunday, January 1, 201779171000108488000
Monday, January 1, 2018168218000244622000
Tuesday, January 1, 2019210796000287000000
Wednesday, January 1, 2020203613000354000000
Friday, January 1, 2021234273000186000000
Saturday, January 1, 2022265784000151000000
Sunday, January 1, 2023344501000232600000
Monday, January 1, 2024267474000
Loading chart...

Unleashing the power of data

Managing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Insmed Incorporated and Ionis Pharmaceuticals, Inc. have been navigating these waters since 2014. Over the past decade, Insmed has seen a steady increase in SG&A costs, peaking at approximately $345 million in 2023. Ionis, on the other hand, experienced a significant rise until 2020, reaching around $354 million, before managing to reduce these expenses by 34% by 2022. This strategic cost management by Ionis highlights their adaptability in a volatile market. Meanwhile, Insmed's consistent rise in expenses suggests a different growth strategy, possibly focusing on expansion and investment. As these companies continue to evolve, their approach to SG&A costs will remain a key indicator of their financial strategies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025